Stroke and transient ischemia are the most common cerebrovascular events in lupus patients, and a new study has found most of these occurrences can be attributed to lupus itself rather than other causes. Click here to find out more.
Congratulations to Dr. Dafna Gladman on receiving the 2018 American College of Rheumatology, Distinguished Clinical Investigator Award. Each year the American College of Rheumatology recognizes its members’ outstanding contributions to the field of rheumatology through an awards program.
The Evelyn V. Hess Award is given annually to recognize the exceptional contributions of a clinical or basic researcher whose body of work has advanced the understanding of the science of lupus treatment. At a reception during the 2018 ACR/ARHP Annual Meeting in Chicago, the Lupus Foundation of America presented the Evelyn V. Hess Award […]
SLE (or lupus for short) is a multisystem, autoimmune disease, involving complex pathogenetic mechanisms that can present at any age. It most commonly presents in women in the reproductive age group, although lupus is increasingly recognized after the age of 40 years, particularly in Europeans…
Systemic lupus erythematosus is a multisystem, chronic autoimmune disease characterised by the presence of antibodies directed at self-antigens, and broad immune dysregulation. It is believed that abnormalities of both the innate and adaptive arms of the immune system, interconnected by a positive feedback loop, contribute to disease pathogenesis.
Ustekinumab is a monoclonal antibody targeting interleukin (IL)-12 and IL-23 and is approved for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn’s disease. IL-12 and IL-23 have been implicated in systemic lupus erythematosus. We aimed to assess the efficacy and safety of ustekinumab for the treatment of systemic lupus erythematosus in patients with moderate-to-severe disease activity despite conventional treatment.
Systemic lupus erythematosus (SLE) is a complex multisystemic autoimmune disease resulting, oftentimes, in irreversible damage, diminished quality of life and reduced life expectancy.1–3 Genetic and environmental factors play important roles in its pathogenesis.4–8 Disease manifestations and severity vary according to the patients’ racial/ethnic background and socioeconomic status (SES).
Dr Marwan Bukhari and Dr John Hanly, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Canada, talk about his paper on the frequency and outcome of lupus nephritis in a prospective SLE inception cohort. In the SLICC inception cohort study, 38% percent of patients developed lupus nephritis within the first 5 years of […]
John Hanly, born in Ireland, obtained his medical degree in 1978 at the National University of Ireland in Cork. Following post-graduate training in Internal Medicine and Rheumatology, he relocated to Canada in 1984 for fellowship training in Clinical Immunology and Rheumatology at the University of Toronto. Additional research training followed at McMaster University and Cornell […]
Dr. Évelyne Vinet, a rheumatologist and an Assistant Professor in the Division of Rheumatology at McGill University’s Faculty of Medicine, has been selected as the 2018 recipient of the Canadian Rheumatology Association’s (CRA) Young Investigator Award. Dr. Vinet, who obtained her PhD from the Department of Epidemiology, Biostatistics and Occupational Health at McGill, focuses her […]